Loading...
*  Dose Finding Study of Pioglitazone in Children With Autism Spectrum Disorders (ASD) (PIO) - Full Text View - ClinicalTrials.gov
The investigators propose a pilot, single blind, placebo run-in, dose finding study of pioglitazone in children with autism with the ultimate goal of identifying appropriate dosing and outcome measures for a larger follow-up randomized placebo controlled clinical trial. The specific aims of this study are: 1) To examine the safety of pioglitazone in children with autism spectrum disorders (ASD) ages 5-12 years; 2) To identify appropriate outcome measures to be used in a follow-up multisite randomized control trial of pioglitazone in children with ASD; 3) To determine the maximum tolerated dose to be used in the follow-up multisite randomized controlled trial; 4) To examine the effect of pioglitazone on markers of inflammation (cytokine levels) and oxidative stress (superoxide dismutase, malonyl aldehydes); 5) To explore the relationship between different doses and response to treatment ...
  https://clinicaltrials.gov/ct2/show/NCT01205282
*  Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment - Full...
Clinical effectiveness is of the finest tools to evaluate treatment success and is combined of 3 elements: treatment effectivity, side effect profile and patient compliance. Since the 3 main PDE5i's differ in their molecular structure, therapeutic profile and pharmacokinetics, it seems logical to assume that combining 2 different PDE5i's at lower dosage each may be beneficial in comparison to a single PDE5i maximal dose therapy. The aim of this study is to compare the clinical effectiveness of combination therapy (2 lower-dose PDE5i's) versus single maximal dose PDE5i therapy ...
  https://clinicaltrials.gov/ct2/show/NCT01364701?recr=Open&cond=%22Genital+Diseases%2C+Male%22&rank=15
*  Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment - Full...
Clinical effectiveness is of the finest tools to evaluate treatment success and is combined of 3 elements: treatment effectivity, side effect profile and patient compliance. Since the 3 main PDE5i's differ in their molecular structure, therapeutic profile and pharmacokinetics, it seems logical to assume that combining 2 different PDE5i's at lower dosage each may be beneficial in comparison to a single PDE5i maximal dose therapy. The aim of this study is to compare the clinical effectiveness of combination therapy (2 lower-dose PDE5i's) versus single maximal dose PDE5i therapy ...
  https://clinicaltrials.gov/ct2/show/NCT01364701?recr=Open&cond=%22Sexual+Dysfunction%2C+Physiological%22&rank=5
*  AID 189219 - Percent reduction of neutrophil accumulatiom with an minimum effective dose of 1 mg/kg when administered orally...
BioAssay record AID 189219 submitted by ChEMBL: Percent reduction of neutrophil accumulatiom with an minimum effective dose of 1 mg/kg when administered orally twice daily for two days before induction of acetic acid-induced colitis in the rat.
  https://pubchem.ncbi.nlm.nih.gov/bioassay/189219
*  AID 167575 - In vitro functional antagonistic testing by obtaining ET-1 concentration response curves in rabbit carotid artery...
BioAssay record AID 167575 submitted by ChEMBL: In vitro functional antagonistic testing by obtaining ET-1 concentration response curves in rabbit carotid artery rings in the presence or absence of antagonist..
  https://pubchem.ncbi.nlm.nih.gov/bioassay/167575
*  Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With...
Corticotropin Releasing Hormone (CRH) is a hypothalamic hormone made up of 41 amino acids. Amino acids are proteins that when combined make up different substances, like hormones. The order of amino acids in CRH, has been determined, meaning that the hormone can now be synthetically reproduced in a laboratory setting.. When CRH is released from the hypothalamus it stimulates the pituitary gland to secrete another hormone, ACTH. ACTH then causes the adrenal glands to make a third hormone, cortisol. This process is known as the hypothalamic-pituitary-adrenal axis. Problems can occur in any of the steps of this process and result in a variety of diseases (Cushing's Syndrome and adrenal insufficiency).. Researchers hope that CRH created in a laboratory setting, ovine CRH (oCRH) can be used to help diagnose and treat conditions of the HPA axis. This study will test the relationship for single doses of oCRH in normal volunteers and patients with disorders of the HPA axis. The oCRH ...
  https://clinicaltrials.gov/show/NCT00001180
*  A Phase II, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Multi-Center, Dose Ranging Study to...
A Phase II, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Multi-Center, Dose Ranging Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Resistant Hypertension ...
  http://adisinsight.springer.com/trials/700040374?error=cookies_not_supported&code=ccb15c60-0e33-456c-8f47-8a3dd94dcde1
*  BrooklynDodger: Human Variability - increased low dose risk
A shallow slope of the exposure response relationship in the observable range in a laboratory bioassay predicts a higher low dose risk; a steep slope a lower low dose risk and thus allows a higher and less protective exposure limit. Increased variability in biological response of the host predicts a shallower exposure response relationship. BrooklynDodger hypothesizes that genetically diverse free living humans show greater variability than genetically homogeneous inbred laboratory housed animals. Therefore, a reference dose established with a dose response relationship in a laboratory study will be underestimate risk in people ...
  http://brooklyndodger1.blogspot.com/2005/05/human-variability-increased-low-dose.html
*  A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension - Tabular View - ClinicalTrials.gov
May or may not have been receiving an approved PDE-5 inhibitor OR an approved ERA.. Subjects receiving an approved ERA or an approved PDE-5 inhibitor must have been on a stable dose for 30 days prior to Baseline, and were willing to remain on a PDE-5 inhibitor or an ERA and at the same dose for the duration of the 12-week Treatment Phase. If a subject chose to discontinue their PDE-5 or ERA prior to entering this study, they must have had a ≥30 day washout period between the last dose of the PDE-5 or ERA and start of the screening phase.. ...
  https://clinicaltrials.gov/ct2/show/record/NCT01104870?term=%22High+Blood+Pressure%22&lup_s=02%2F01%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14
*  A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension - Study Results - ClinicalTrials.gov
Restriction Description: Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed, except as provided below. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation ...
  https://clinicaltrials.gov/ct2/show/results/NCT01104870?term=%22High+Blood+Pressure%22&lup_s=02%2F01%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14
*  BT GS 1.3 Dose response curves and associated terms | Primary LO of the Day
This is one of my favourite topics to ask in vivas. It is very easy to get yourself confused unless you have things clear in your head. Practise, practise, practise..... BT_ GS 1.3 Define and explain dose-effect relationships of drugs with reference to: · Graded and quantal response · Therapeutic index · Potency and efficacy ·…
  https://primarydailylo.wordpress.com/2017/02/07/%EF%BB%BFbt_gs-1-3-dose-response-curves-and-associated-terms/
*  Vitamin D Dose Finding Study - Study Results - ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
  https://clinicaltrials.gov/ct2/show/results/NCT01092338?sect=X80156&view=results
*  Abstract 307: Enhancement of Cerebrovascular Relaxation by Angiotensin II Type 2 Receptor Agonist, C21, is Lost in Type 2...
Background: Angiotensin type 1 receptor (AT1R) blockers provide vascular protection and improve stroke outcomes in young otherwise healthy animals. These effects are believed to be mediated by the indirect stimulation of AT2R signaling. The AT2R agonist, compound 21 (C21), improves endothelial function in peripheral vascular beds but its effect on cerebral endothelial function remains unknown. It is important to determine the vascular effects of C21 in diabetes, a comorbid condition which is known to worsen stroke outcomes.. Methods: Endothelium-dependent relaxation was assessed in male Wistar and Type 2 diabetic Goto-Kakizaki (GK) rats (n=3-6) by measuring acetylcholine (ACh, 1 nM - 5 μm) induced dilatory response in basilar arteries. In a subset of experiments C21 dose response curves were generated (0.1 nM - 1 μM) or vessels were pre-incubated with 100 nM C21 ± 1 μM PD123319 (AT2R blocker) for 30 min prior to Ach dose ...
  http://hyper.ahajournals.org/content/64/Suppl_1/A307
*  Plus it
The identification of molecules involved in the mitogenic signaling and participating to the process of neoplastic transformation and progression has fostered the synthesis of novel agents able to selectively down-regulate such targets. PKAI seems to be one of such relevant targets suitable for therapeutic intervention, and antisense oligonucleotides against its RIα subunit have shown promising results in inhibiting human cancer cell growth in vitro and in vivo (9, 10, 11, 12 , 15) .. In the present study, we have demonstrated that HYB 165, a novel DNA/RNA hybrid MBO with improved pharmacokinetic and bioavailability properties in vivo, exhibits a dose-dependent inhibitory effect on soft agar growth of ZR-75-1 breast cancer cells.. We have also shown that HYB 165, but not its control oligo HYB 508, has a synergisitic inhibitory effect on ZR-75-1 colony formation when used in combination with docetaxel, a cytotoxic drug very active in breast cancer patients (26) . The ...
  http://clincancerres.aacrjournals.org/content/5/4/875
*  Dose dependent effects measured in panel of steroid com | Open-i
Dose dependent effects measured in panel of steroid compounds.The differential effects of various steroidal compounds on AR nuclear translocation, nuclear hyper
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC2572143_pone.0003605.g004&req=4
*  Dose Ranging Study of Albiglutide in Japanese Subjects - Tabular View - ClinicalTrials.gov
Clearance is defined as the volume of plasma cleared of albiglutide per unit time. Samples were collected prior to the administration of study medication on dosing days (Weeks 0, 1, 4, 5, 8, 12, and 13) and on the day of the clinic visit at Weeks 16, 20, and 24. At Weeks 0, 1, 4, 8, and 12, pharmacokinetic (PK) samples were collected immediately prior to dosing if a dose was scheduled for that week. At Weeks 16, 20, and 24, PK samples were collected at any time during the visit. The Week 5 post-dose PK sampling was performed any time between Weeks 4 and 6, within 2 to 5 days after administration of a dose; Week 13 post-dose PK sampling was performed any time between Weeks 12 and 14, within 2 to 5 days after administration of a dose of study medication. Modeled population PK data are presented; data were analyzed using a non-linear mixed effect modeling approach. A one-compartment PK model with first-order absorption and ...
  https://clinicaltrials.gov/ct2/show/record/NCT01098461
*  A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1...
This is a two phase study (randomised and non-randomised phase). The randomised phase will initially examine 4 blinded doses of GW640385 boosted with rtv (with continuation of current background therapy) in comparison to an ongoing, open-labeled rtv-boosted protease inhibitor (PI) regimen for 15 days. At the Day 15 visit, all subjects will optimize background therapy. Additionally, subjects receiving the lowest dose of GW640385 will be re-randomised to one of the higher doses and subjects in the control arm will receive a new rtv-boosted PI based on resistance testing at screening. Subjects will remain in the randomized phase on one of these 4 continuing treatment arms for at least 48 weeks. An interim analysis will occur during the randomised phase to select for a dose of GW640385 to evaluate further in Phase III studies. After dose selection subjects will move to the non-randomised phase of the study. In the non-randomised ...
  https://clinicaltrials.gov/ct2/show/study/NCT00242879?show_locs=Y
*  A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1...
This is a two phase study (randomised and non-randomised phase). The randomised phase will initially examine 4 blinded doses of GW640385 boosted with rtv (with continuation of current background therapy) in comparison to an ongoing, open-labeled rtv-boosted protease inhibitor (PI) regimen for 15 days. At the Day 15 visit, all subjects will optimize background therapy. Additionally, subjects receiving the lowest dose of GW640385 will be re-randomised to one of the higher doses and subjects in the control arm will receive a new rtv-boosted PI based on resistance testing at screening. Subjects will remain in the randomized phase on one of these 4 continuing treatment arms for at least 48 weeks. An interim analysis will occur during the randomised phase to select for a dose of GW640385 to evaluate further in Phase III studies. After dose selection subjects will move to the non-randomised phase of the study. In the non-randomised ...
  https://clinicaltrials.gov/show/NCT00242879?order=32
*  Plus it
In this first-in-human study, a single procedure endoscopic DMR ablation elicited a substantial improvement in glycemia in medically treated patients with suboptimally controlled type 2 diabetes followed for 6 months, with an acceptable safety and tolerability profile observed to date.. DMR appeared to exhibit dose dependency, with LS ablation exerting more potent glycemic effects, as seen by the statistically significant difference in glycemic effect between SS-DMR versus LS-DMR at 3 months (P , 0.05). This is stated with some caution, as the study was not designed to formally examine ablation dose dependency (i.e., SS vs. LS ablation), and the optimal length of ablated duodenum requires additional study. As one would anticipate with a novel, procedure-based intervention, this first-in-human study was conducted in an iterative manner where procedural feasibility and patient safety were of prime importance in the earlier cases. As procedural expertise increased, LS ablation ...
  http://care.diabetesjournals.org/content/39/12/2254
*  OhioLINK ETD: Kathayat, Dipak
Here, using a Tecan Sunrise™ absorbance plate reader, a pre-selected enriched SM library containing 4,182 SMs was screened at 100 µM concentration against a predominant field APEC serotype, APEC O78, grown in minimal M63 media. Of the total 4,182 SMs, 41 SMs inhibited APEC O78 growth. The majority of growth inhibitory SMs were found belonging to chemical groups; quinolines, piperidines, pyrrolidinyls, and imidazoles. Among 41 SMs, 30 SMs exhibited bacteriostatic activity, while remaining 11 SMs displayed bactericidal activity and were selected for further studies. Dose-response analysis of these selected SMs revealed their dose-dependent activity with minimal inhibitory concentration (MIC) ranging 12.5 µM to 200 µM. These selected SMs were found broadly effective against various APEC serotypes such as O1, O2, O8, O15, O18, O35, O109, and O115. Six of these SMs exhibited narrow-spectral activity affecting 1-3 tested commensal bacteria. Except SM11, other SMs ...
  https://etd.ohiolink.edu/pg_10?0::NO:10:P10_ETD_SUBID:151808